Daily Stock Analysis, CBPO, China Biologic Products Holdings Inc, priceseries

China Biologic Products Holdings Inc. Daily Stock Analysis
Stock Information
Open
93.71
Close
93.00
High
93.71
Low
92.48
Previous Close
93.64
Daily Price Gain
-0.64
YTD High
101.23
YTD High Date
Apr 29, 2019
YTD Low
73.00
YTD Low Date
Jan 3, 2019
YTD Price Change
19.05
YTD Gain
25.76%
52 Week High
105.50
52 Week High Date
Aug 20, 2018
52 Week Low
60.08
52 Week Low Date
Oct 26, 2018
52 Week Price Change
-9.46
52 Week Gain
-9.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 6. 2017
102.02
May 4. 2017
115.49
19 Trading Days
13.20%
Link
LONG
Apr 2. 2019
92.83
May 1. 2019
98.19
20 Trading Days
5.77%
Link
Company Information
Stock Symbol
CBPO
Exchange
NasdaqGS
Company URL
http://www.chinabiologic.com
Company Phone
86-10-6598-3111
CEO
Xiao Ying Gao
Headquarters
-
Business Address
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT, BEIJING, CHINA 100125
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001369868
About

China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances. Its products include human albumin, human immunoglobulin for intravenous injection, human Hepatitis B immunoglobulin, human rabies immunoglobulin, human immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, and placenta polypeptide. The company was founded on December 20, 1989 and is headquartered in Beijing, China.

Description

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (pH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; human cytomegalovirus immunoglobulin; human coagulation factor IX; and human fibrin sealant products. The company sells its products directly, as well as through distributors. China Biologic Products, Inc. is headquartered in Beijing, the People's Republic of China.